ArticleWorld journal of gastrointestinal oncology2022

Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma.

Xi Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.